BioCentury
ARTICLE | Clinical News

CVac: Phase II final data

May 25, 2015 7:00 AM UTC

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Product: CVac Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: Ex vivo cancer vaccine using a patient’s own dendriti...